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Abstract 
Objectives: Attention-deficit hyperactivity disorder (ADHD) is a common behavioural 
disorder that affects not only children and adolescents but also adults; however, diagnosis of 
adult-ADHD is difficult because patients seem to have reduced externalized behaviour. 
ADHD is a multifactorial disorder in which many genes, all with small effects, are thought to 
cause the disorder in the presence of unfavourable environmental conditions. 
Methods: Therefore, in this pilot study we explored the expression profile of a list of 
previously established candidate genes in peripheral blood samples from adult-ADHD 
subjects (n=108) and compared these results to those of healthy controls (n=35). 
Results: We demonstrate that combining the gene expression levels of dopamine transporter 
(SLC6A3), dopamine D5 receptor (DRD5), tryptophan hydroxylase-1 (TPH1), and SNAP25 as 
predictors in a regression model resulted in sensitivity and specificity of over 80% (ROC: 
max R²=0.587, AUC=0.917, P<0.001, 95% CI: 0.900–0.985). 
Conclusion: In conclusion, the combination of these four genes could represent a potential 
method for estimating risk and could be of diagnostic value for ADHD. Nevertheless, further 
investigation in a larger independent population including different subtypes of ADHD 
(inattentive, hyperactive, or combined type) patients is required to obtain more specific sets of 
biomarkers for each subtype as well as to differentiate between child, adolescent, and 
adulthood forms. 
 
Key Words: Genetic, Adult ADHD, Peripheral, biomarker, Biological Psychiatry 
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Introduction 
Attention-deficit hyperactivity disorder (ADHD) is one of the most common behavioural 
disorders in child and adolescent psychiatry (prevalence variance of 5–12%) (Faraone et al. 
2003; Polanczyk et al. 2007), while recently it was demonstrated in adults with a prevalence 
variance of 3–6% (Klassen et al. 2010; Simon et al. 2009; Lara et al. 2009). The disorder is 
characterized by impaired attention, motor hyperactivity, and increased impulsivity (Haavik et 
al. 2010; American Psychiatric Association 2000). Adult ADHD is a well characterized 
condition, although it is generally accepted that the onset of ADHD usually occurs in 
childhood (Biederman 2005; American Psychiatric Association 2000). The diagnosis and 
treatment of adult ADHD can be challenging since hyperactive symptoms and externalized 
behaviours tend to wane with age, making diagnosis difficult (Klassen et al. 2010).  
Despite evidence pointing towards a primarily genetic basis for ADHD, no specific genetic 
variants are yet known (Wood and Neale 2010; Banaschewski et al. 2010; Franke et al. 2009). 
The candidate genes explored so far confirm only small to moderate effects, with odds ratios 
(OR) ranging from 1.03–1.83 (Faraone and Mick 2010). The most frequently studied genes 
affecting the susceptibility to ADHD are the dopamine D4 receptor (DRD4), DRD5, 
dopamine transporter (SLC6A3, DAT1), 25-kDa synaptosomal-associated protein (SNAP25), 
serotonin transporter (SLC6A4, SERT), and tryptophan hydroxylase 2 (TPH2) (Faraone and 
Mick 2010; Gizer et al. 2009), but all seem to have mild effects. Additionally, environmental 
factors like stress and prenatal alcohol or nicotine consumption could also influence the 
ADHD phenotype and prevalence, which are part of many components regarded as Gene x 
Environmental interaction (Nigg et al. 2010). Therefore, there is probably no single gene 
indicating the presence of ADHD, but rather polygenetic markers that in combination increase 
the risk for the disorder. Such an approach, using a wide array of parameters, is referred to as 
biomarkers.  
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Biomarkers can be used as diagnostic tools to identify or stage disease, as indicators of 
disease prognosis or predictors, or to monitor clinical response to therapy. As defined by the 
Biomarkers Definitions Working Group, a biomarker is “a characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic processes, 
or pharmacologic responses to a therapeutic intervention” (Biomarkers Definitions Working 
Group 2001). Consequently, in this pilot study we explore a group of candidate genes 
comprising the described risk genes known in the literature (Faraone and Mick 2010; Gizer et 
al. 2009), and corticotropin-releasing factor binding protein (CRHBP) was selected as a 
response to stress, which is also thought to be a risk factor for ADHD, to assess their 
expression profile in peripheral blood samples taken from adult ADHD subjects compared 
with samples from healthy controls. Such concept was previously reported in which 
transcriptional profiling resulted in identification of several candidate genes in blood and 
brain, especially for schizophrenic patients (Glatt et al. 2005; Tsuang et al. 2005; Mehler-Wex 
et al. 2006; Noori-Daloii et al. ; Taurines et al. 2010) and Alzheimer’s and Parkinson’s 
disease patients (Grünblatt et al. 2009; Grünblatt et al. 2010; Scherzer et al. 2007).  
The concept of peripheral blood cells as a “window” into the central nervous system (CNS) 
was proposed nearly a decade ago (Gladkevich et al. 2004; Burczynski and Dorner 2006), 
whereas CNS versus peripheral expression has proven to moderately correlate (Sullivan et al. 
2006; Cai et al. 2010). We hypothesised that none of the biomarkers would individually 
provide high sensitivity and specificity; therefore, we used the best known candidates in a 
combined gene expression analysis and a comprehensive regression model. 
Methods 
Subject recruitment 
Patients and controls were recruited and phenotypically characterized by a team of 
experienced psychiatrists at the outpatient units of the Department of Psychiatry, 
Psychosomatics, and Psychotherapy, University of Würzburg, Germany, according to DSM-
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IV criteria (American Psychiatric Association 2000; Jacob et al. 2007). The diagnosis of 
childhood and youth manifestation of ADHD was retrospectively assessed with the DSM-IV 
symptom list for ADHD, which was used as a structured clinical interview. Additional 
information from parents and school report cards was included if available. Adult 
symptomatology was assessed with the DSM-IV symptom list for ADHD. To ensure 
diagnostic validity, informative input from partners, relatives, and friends was also collected. 
Co-morbidity was assessed with the structured clinical interviews of axis I (SCID I) disorders 
(First et al. 1997). Exclusion criteria were: autistic disorder, psychotic disorder, bipolar 
affective disorder, history of epilepsy, other neurologic disorder, severe chronic medical 
condition, IQ < 80 (Jacob et al. 2007). Additionally, detailed information on medication, 
alcohol abuse, and smoking habits was collected. Control subjects underwent diagnostic 
procedures similar to those of the patients to exclude any other psychiatric disorders. Controls 
were recruited through local newspaper ads. The subjects provided informed consent 
according to the Helsinki Declaration. The study protocol was approved by the local ethics 
committee of the Universities of Würzburg, Germany. Written informed consent was obtained 
from all subjects or their primary caregivers. 
One hundred and eight patients diagnosed with ADHD (46 males and 62 females) and 35 
healthy controls (19 males and 16 females) were included in this study (Table S1, 
supplemental data). All subjects were with German ancestry that ensured a homogenous 
sample analysis. The gender distribution was similar in both diagnostic groups (P=0.247, 
Table S1), whereas the mean age was significantly older in the control group (controls = 
39.6±9.49 years, ADHD = 34.7±10.52 years; P=0.009). The most frequent lifetime co-
morbidities were substance-related disorders (alcohol 11.1%, cannabis 22.2%), and other co-
morbidities were present in 11.1% of patients. In ADHD patients, the combined subtype was 
diagnosed in 70.4% (n=76), whereas 21.3% (n=23) were primarily inattentive, and 5.5% 
(n=6) were primarily hyperactive. Whole blood was collected with the PAXgene™ Blood 
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RNA system (Becton Dickinson GmbH, Heidelberg, Germany), and EDTA-blood tubes. 
Blood samples were frozen at -20C until further processing for total RNA extraction, 
whereas fresh blood was processed immediately for DNA isolation. 
Genomic DNA extraction 
DNA was prepared from 2 ml EDTA-blood using proteinase K as described previously 
(Grünblatt et al. 2005). The DNA was then aliquoted into cryo-Vials (Nunk GmbH, 
Wiesbaden, Germany) and frozen at -70
0
C until processing. 
Genotyping 
Genotyping was conducted as previously described for SNAP25 +2015 (rs6077690), SNAP25 
+80609 (rs363006), SNAP25 -523 (rs6039769) (Renner et al. 2008), serotonin transporter 
linked polymorphic region (HTTLPR; SLC6A4 tri allelic) (Lesch et al. 1996; Hu et al. 2005), 
TPH2 SNP25 (rs4570625) (Walitza et al. 2005), SLC6A3 3’UTR VNTR, and DRD4 exon 3 
VNTR (Walitza et al. 2008). 
Total RNA extraction 
Total RNA was prepared with the PAXgene™ Blood RNA Kit 50 (PreAnalytiX, Qiagen and 
BD, Germany). RNA isolation reagents were prepared from 0.2 M filtered, diethyl 
pyrocarbonate (DEPC)-treated water (Fermentas Inc., Hanover, MD, USA) throughout the 
isolation procedure. Total RNA samples were spectrophotometrically scanned (Experion, 
BioRad Co., Hercules, CA, USA) from 220 to 320 nm; the A260/A280 of total RNA was 
typically >1.9.  
Quantitative real-time RT-PCR analysis 
Quantitative real-time RT-PCR was used for 7 genes (Table S2, supplemental data) as 
follows: SLC6A3; DRD4; DRD5; TPH1 (variant 1 was tested in the peripheral samples since 
variant 2 [TPH2] is not expressed in the peripheral blood but only in the CNS); SLC6A4; 
SNAP25; CRHBP; additionally, 6 reference genes were used as internal controls. Total RNA 
(500 ng) from each sample was reverse transcribed with the random hexamer & oligo-dT 
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primer mix using iScript (BioRad Co., Hercules, CA, USA). Quantitative real-time PCR was 
performed in the iCycler iQ system (BioRad Co., Hercules, CA, USA) as described 
previously (Grünblatt et al. 2009). Real-time PCR was subjected to thermocycler 
amplification as described previously (Grünblatt et al. 2009). All PCR reactions were run in 
duplicate. The amplified transcripts were quantified using the comparative CT method 
analyzed with the BioRad iCycler iQ system program. Gene expression levels were 
normalized to the 6 reference genes according to GeNorm (Vandesompele et al. 2002). Data 
was analyzed with Microsoft Excel 2000 to generate raw expression values. 
Statistical analysis 
Because of non-normal data distribution, parametric procedures including all potential 
moderating variables could not be employed; therefore, we tried to control for the influence of 
age on individual mRNA levels by looking at the correlation between age and gene 
expression. The relationship between genotype, diagnosis, and gender was explored with a 
Chi² test on 2 (diagnosis) x 3 (genotype) cross-tabs both with gender as a layer variable for 
each gene and for both genders combined. For analysis of our main variable of interest – gene 
expression differences between diagnostic groups – non-parametric Mann-Whitney-U tests 
for differences in mean rank between ADHD subjects and controls were performed. For those 
genes returning significant main effects of diagnosis, we also checked for the influence of 
genotype on gene expression within each diagnostic group.  
Assuming a combination of markers would yield the best prediction, we employed binary 
logistic regression to first assess the diagnostic utility of the expression of our candidate genes 
for the ability to differentiate between ADHD patients and healthy controls. To that end, we 
entered those genes showing differential expression between ADHD and controls as well as 
the potentially confounding variables age and gender into the model. We applied a filter 
excluding cases rated as outliers on any one of the respective RNA levels. Outliers were 
identified using Box plots, with values more than 1.5 and 2 box-lengths away from the box 
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ends are characterised as such. In total, 19 samples had to be excluded, because they were 
classified as outliers on the expression level of at least one gene. The predicted probabilities 
from significant predictors from this whole model were then ultimately used for building a 
receiver operating characteristic (ROC) curve and assessing sensitivity and specificity. Since 
odds ratios (OR) were extremely large due to the small unit of the detected gene expression 
levels (e.g. 6666.13 for TPH1), the original mRNA values were multiplied by a factor of 100. 
Significances remained unchanged by this procedure. The significance level was set as 0.05 
(nominal p-values). All computations were completed using the statistical computing 
environment, PASW Statistics 18. 
Results 
All genotypes were in Hardy-Weinberg-Equilibrium. For exact genotype distributions, see 
supplementary Table S3. From the results of the different genotypes, we detected no 
association between ADHD and any of the polymorphisms. 
Except for lower TPH1 levels (r=-0.174, P=0.039) being weakly associated with older age, no 
significant correlations between age and any of the genes were observed (all P>0.105; for 
details, see supplementary data, Table S4). 
The dopaminergic system showed the most prominent differences between ADHD patients 
and controls, with patients having elevated SLC6A3 expression (P=0.001), and both DRD4 
and DRD5 showed higher expression levels in ADHD patients compared with controls 
(P=0.005 and P<0.001, respectively; Table 1; supplementary Figure S1). Furthermore, there 
was a notable increase in SNAP25 in samples from ADHD subjects compared with controls 
(P=0.01). With regard to the serotonergic genes, no difference was found for SLC6A4 
(P=0.696); however, ADHD subjects had higher expression of the rate-limiting enzyme TPH1 
mRNA (P<0.001). CRHBP mRNA was the only gene expressed at lower levels in ADHD 
cases (P=0.037). Within the diagnostic groups, no influence of genotype on gene expression 
was observed (Table 1; Supplementary Figure S2). 
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For our first binary logistic regression model we used a forward stepwise approach, in which 
all variables were successively entered. In this case, we used the expression levels of all 
candidate genes (SLC6A3, DRD4, DRD5, TPH1, SNAP25 and CRHBP) along with age and 
gender as potential predictors. Concerning multicolinearity, all correlations of variables 
within this model were below 0.510. The whole model returned the following significant 
regressors: DRD5 (p=0.011, OR=1.40, 95% CI: 1.08–1.81), TPH1 (p<0.009, OR=1.10, 95% 
CI: 1.02–1.17) and SNAP25 (p=0.021, OR=1.07, 95% CI: 1.01–1.13) and a trend-level 
contribution for SLC6A3 (p=0.069, OR=1.06, 95% CI: 1.00–1.13) (Supplementary Table S5). 
The receiver operating characteristic (ROC) curve was built using these four genes (Figure 1: 
max R²=0.587, AUC=0.917, P<0.001, 95% CI: 0.900–0.985). Combining gene expression 
levels of SLC6A3, DRD5, TPH1, and SNAP25 as predictors in a regression model, 80% of 
cases could be correctly classified as ADHD subjects or controls. Any other combination with 
other genes or with three or two of the above four resulted in a worse prediction of ADHD 
compared with this four-gene combination. We achieved sensitivity and specificity of over 
80% (e.g. sensitivity of 81% and specificity of 82% at a cut-off of 0.69) according to the 
whole-model ROC analysis. The combined approach was superior to any individual variables 
predictive ability, where separate logistic models returned the following results: SLC6A3 
(AUC=0.694, sensitivity = 0.696, specificity = 0.645), DRD5 (AUC=0.749, sensitivity = 
0.752, specificity = 0.625), SNAP25 (AUC=0.689, sensitivity = 0.637, specificity = 0.618) 
and TPH1 (AUC=0.812, sensitivity = 0.776, specificity = 0.706). 
Discussion 
We showed that a combination of expression patterns for four ADHD-associated genes in the 
peripheral blood of adult ADHD patients could be a potential method for estimating risk and 
have possible diagnostic value for ADHD. Since ADHD is a heterogeneous disorder with a 
high comorbidity rate, a complex diagnostic tool with more than one marker was expected 
(Wallis 2010). We show that a combination of expression levels of four genes, SLC6A3, 
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DRD5, TPH1 and SNAP25, provide relatively high sensitivity and specificity, indicating the 
potential use of this combination of biomarkers to identify the risk of ADHD in adults. Three 
of the genes studied were unaffected by age, whereas TPH1 showed a very mild decrease in 
expression with age. Recently, in a study for mRNA alterations in whole blood from child and 
adolescent ADHD compared to autism spectrum disorder (ASD) and to controls no group 
differences were found for TPH1 mRNA expression (Taurines et al. 2011) Still, TPH1 
expression of the ADHD group (n=51) was slightly higher than the ASD (n=26) or the control 
(n=39) group (Taurines et al. 2011), which might indicate the beginning of alterations with 
age for ADHD group. As an additional parameter, we analysed the association of the 
genotypes for the same genes studied with ADHD. We observed no overall association 
between genotype and ADHD for any of the genes tested; moreover, we checked for an 
additional influence of genotype on the mRNA levels of those genes found to be differently 
expressed in patients and controls; however, this also showed no difference. Since transcript 
expression seems to be influence rather by multiple factors such as multiple genetic 
polymorphism as well as environmental factors, the notion that multiple transcript analysis 
would be necessary to identify ADHD cases is pointed out. 
The four candidate genes identified as the best biomarkers in this study were previously 
described in other ADHD association studies (Stergiakouli and Thapar 2010; Gizer et al. 
2009). The most consistent evidence for an association with ADHD exists for the DRD5 gene 
microsatellite (Squassina et al. 2008) and the SLC6A3 gene variable tandem repeat (VNTR) 
at the 3’ UTR (Stergiakouli and Thapar 2010; Gizer et al. 2009). In contrast, very weak 
individual associations were reported for TPH1 (Gizer et al. 2009; Johansson et al. 2010) and 
SNAP25 (Gizer et al. 2009; Forero et al. 2009; Kim et al. 2007), but the 3’ UTR of the latter 
was significant in a recent meta-analysis (Gizer et al. 2009). Each of these genes often showed 
a very modest genetic effect on the risk of ADHD (meta-analysis: SLC6A3 10 repeats 
OR=1.1, 95% CI: 1.03–1.17; DRD5 5’ Flank OR=1.22, 95% CI: 1.10–1.36; TPH1 intron 6 
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OR=0.99, 95% CI: 0.89–1.10; SNAP25 3’ UTR OR=1.15, 95% CI: 1.01–1.31) (Gizer et al. 
2009). Interestingly, SLC6A3 seems to have an opposite effect in persistent adult ADHD 
compared with childhood ADHD (Franke et al. 2010). Therefore, the need for sensitive 
biomarkers that in combination achieve a much higher OR than the ones investigated to-date 
is necessary. In our study, we combined multiple genetic markers with relatively good 
success, which confirms the potential of this strategy. 
A limitation of this study is the small sample size; however, since this was planned as an 
exploratory study the sample size still pointed to the possible candidate genes that should be 
than confirmed in the future. Additionally, the different co-morbidities existing in our 
population might have affected the results, which we could not control for properly because of 
the limited group size. Since adult ADHD is highly co-morbid with other ICD diagnoses 
(Wallis 2010), there might be common pathways for the array of these disorders that still 
provides a good diagnostic tool. It will be necessary to look at subgroups in future studies 
with a larger population, and to analyze markers for a specific diagnosis. Furthermore, a 
larger population would enable us to incorporate the different pharmacological treatments to 
rule out any effects of these on gene expression. The biggest limitation might be the fact that 
the populations we examined and determined the test’s sensitivity and specificity from were 
extensively evaluated by trained professionals and the subjects included in the study had 
either a very clear-cut case of ADHD or were completely healthy. However, in real-life 
patients, presentations are often a lot more ambiguous, making the development of a highly 
sensitive and specific test a top priority. In that case, our markers might do less well, so 
results need to be validated with a broader spectrum of ADHD phenotypes and severities and 
the predictive value needs to be determined. 
 
In conclusion, we demonstrate the potential of peripherally-expressed genes as biomarkers 
that could be used to diagnose ADHD. Further investigation of additional candidate 
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transcripts in a larger independent population including different ADHD sub-groups 
(inattentive, hyperactive, and combined type) and compare it not only to healthy controls but 
also to other psychiatric disorders is required to obtain more specific sets of biomarkers for 
each sub-disorder and to differentiate between childhood, adolescent, and adult forms of 
ADHD. 
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Figure legend: 
Figure 1: Receiver operating characteristic (ROC) curve for the candidate markers, dopamine 
transporter (SLC6A3), dopamine D5 receptor (DRD5), tryptophan hydroxylase 1 (TPH1), and 
synaptosomal-associated protein of 25 kDa (SNAP25) mRNA. 
 
Supplementary figures: 
Figure S1: Gene expression levels in peripheral blood samples of attention-deficit 
hyperactivity disorder (ADHD) patients compared with controls. Statistical significance 
*P<0.05, **P<0.0001. Annotation: SLC6A3, dopamine transporter (DAT); DRD4, dopamine 
D4 receptor; DRD5, dopamine D6 receptor; CRHBP, corticotropin-releasing factor binding 
protein; SNAP25, synaptosomal-associated protein of 25 kDa; TPH1, tryptophan hydroxylase 
1; SLC6A4, serotonin transporter. 
Figure S2: Gene expression levels in peripheral blood samples from attention-deficit 
hyperactivity disorder (ADHD) patients compared with controls showing the genotype 
influence of expression. The genotypes are: SNAP25 +2015 (rs6077690), +80609 (rs363006), 
-523 (rs6039769), TPH2 (rs4570625), and SLC6A3 (3’UTR VNTR). Statistical significance 
*P<0.05, **P<0.001. Annotation: SLC6A3, dopamine transporter (DAT); SNAP25, 
synaptosomal-associated protein of 25 kDa; TPH1, tryptophan hydroxylase 1; TPH2, 
tryptophane hydroxylase 2.  
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Table 1: Gene expression patterns in attention-deficit hyperactivity disorder (ADHD) patients 
versus control subjects and genotype effects. 
  ADHD subjects 
(mean ± SD)  
 Controls subjects 
(mean ± SD)  
P  Genotype Effects 
(P-values) 
ADHD Controls 
SLC6A3  .37 ± .19 > .25 ± .09 0.001 .537 .783 
DRD4 .36 ± .27 > .24 ± .14 0.005 .684 .206 
DRD5 .13 ± .09 > .07 ± .04 <0.001 
N/A N/A 
CRHBP .17 ± .11 < .21 ± .12 0.037 
SNAP25 .41 ± .29 > .24 ± .08 0.001 .311 .126 
TPH1 .44 ± .30 > .19 ± .06 <0.001 .800 .598 
SLC6A4 .16 ± .09  .17 ± .09 N/S N/D N/D 
Annotation: N/A, data not available since no genotyping was conducted; N/S, not significant; 
N/D, not done (since the main result was not significant); SLC6A3, dopamine transporter 
(DAT); DRD4, dopamine D4 receptor; DRD5, dopamine D6 receptor; CRHBP, corticotropin-
releasing factor binding protein; SNAP25, synaptosomal-associated protein of 25 kDa; TPH1, 
tryptophan hydroxylase; SLC6A4, serotonin transporter. 
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Table 2: Individual logistic regression models for each biomarker 
 P-value  OR (95% CI) AUC 
Age 0.018 0.95 (0.92–0.99) 0.646 
Gender 0.229 0.63 (0.29–1.35) 0.558 
SLC6A3 0.003 1.06 (1.02–1.10) 0.694 
DRD4 0.015 1.04 (1.01–1.06) 0.656 
DRD5 0.001 1.21 (1.08–1.35) 0.749 
CRHBP 0.074 0.97 (0.94–1.00) 0.381 
SNAP25 0.002 1.05 (1.02–1.08) 0.689 
TPH1 < 0.001 1.09 (1.05–1.14) 0.812 
SLC6A4 0.705 0.99 (0.95–1.04) 0.478 
OR: higher value refers to attention-deficit hyperactivity disorder (ADHD) cases, P <0.05 
(uncorrected). 
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Annotation: AUC = area under the curve (for gender 1= male, 2 = female); OR, odds ratio; 
SLC6A3, dopamine transporter (DAT), DRD4, dopamine D4 receptor; DRD5, dopamine D6 
receptor; CRHBP, corticotropin-releasing factor binding protein; SNAP25, synaptosomal-
associated protein of 25 kDa; TPH1, tryptophan hydroxylase; SLC6A4, serotonin transporter. 
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Supplementary Table S1: Characteristics of the attention deficit disorder hyperactivity 
(ADHD) patients and controls. 
 ADHD 
(N = 108) 
Controls 
(N = 35) 
 
Mean SE Mean SE p 
Age (years) 34.70 1.61 39.63 1.02 .009 
 
 N % N % p 
Gender (male) 46 54.3 19 42.6 .247 
Medication
a
              Yes 
                                   No 
                        Unknown  
32 
55 
21 
29.6 
50.9 
19.4 
0 0 n.a. 
Comorbidities lifetime 
 Alcohol 
 Cannabis 
 Other 
 
12 
24 
12 
 
11.1 
22.2 
11.1 
 
 
- 
 
 
 
- 
 
 
.034 
.002 
.034 
Comorbidities current 
 Alcohol 
 Cannabis 
 Otherb 
 
7 
3 
1 
 
6.5 
2.8 
0.9 
 
 
- 
 
 
 
- 
 
 
n.s.  (.122) 
n.s.  (.073) 
n.s.  (.097) 
                                                                      ADHD 
 N child N child % N adult N adult %  
Subtypes
c 
 inattentive 
 hyperactive 
 combined 
 
35 
9 
58 
 
32.4 
8.3 
53.7 
 
23 
6 
76 
 
21.3 
5.5 
70.4 
 
a
 Medication- methylphenidate. 
b
 Other comorbidities- sedatives, stimulants, opiates, cocaine, hallucinogen, multiple drug 
dependency, etc. 
c
 Missing values might lead to differences in total numbers 
n.s not significant; ADHD, attention-deficit hyperactivity disorder; SE, standard error. 
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Supplementary Table S2: List of genes investigated 
Gene Name Symbol 
Gene Bank 
Accession 
Number 
Qiagen 
Primer Assay 
Cat. No. 
18s ribosomal R18S V01270 QT 00199367 
Beta-actin ACTB NM_001101 QT 00095431 
Aminolevulinate delta synthase 1 ALAS1 NM_000688 QT 00073122 
Glyceraldehydes-3-phosphate 
dehydrogenase 
GAPDH NM_002046 
QT 00079247 
Ribosomal protein L13a RPL13A NM_012423 QT 00089915 
Peptidylprolyl isomerase A (cyclophilin A) PPIA NM_021130 QT 01669542 
Solute carrier family 6 (Neurotransmitter 
transporter, dopamine member 3) 
SLC6A3 
(DAT1) 
NM_001044 
F: 5´CTC TGC 
GAG GCG TCT 
GTT 3´ 
 
R: 5´AGC TGG 
AGA AGG CGA 
TCA G 3´ 
Dopamine receptor D4 DRD4 NM_000797 QT00204316 
Dopamine receptor D5 DRD5 NM_000798 QT00217651 
Tryptophan Hydroxylase 1 TPH1 NM_004179 QT00045346 
Solute carrier family 6 (neurotransmitter 
transporter, serotonin), member 4 
SLC6A4 
(SERT) 
NM_001045 QT00058380 
Synaptosomal-associated protein 25 kDa SNAP25 NM_003081 QT00028546 
Corticotropin-releasing factor binding protein CRHBP NM_001882 QT00019257 
Bold- Reference genes 
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Supplementary Table S3: Genotype and allele frequencies for attention-deficit hyperactivity 
disorder (ADHD) patients and healthy controls. 
Gene Genotype 
HWE 
Allele-frequencies  P 
Chi² P 
SNAP25 
+2015 (rs6077690) 
 
 
+80609 (rs363006) 
 
 
-523 (rs6039769) 
  
 AA AT TT  A (%) T (%) A/T  
 
.166 
ADHD 17 57 33 .86 .35 91 (43) 123 (57) .73 
controls 9 19 6 .54 .46 37 (54) 31 (46) 1.19 
 
 AA AG GG  A G A/G  
 
.061 
ADHD 4 32 71 .03 .87 40 (19) 174 (81) .23 
controls 0 6 28 .32 .57 6 (9) 62 94) .10 
 
 AA AC CC  A C A/C  
 
.079 
ADHD 9 48 50 .28 .59 66 (31) 148 (69) .45 
controls 6 17 11 .02 .897 29 (43) 39 (57) .74 
SERT  
(HTTLPR tri-allelic) 
  SS SL LL  S L S/L  
 
.888 
ADHD 20 51 36 .07 .797 91 (43) 123 (57) .73 
controls 6 18 10 .18 .668 30 (44) 38 (56) .79 
TPH2 (rs4570625)   AA AC CC  A C A/C  
 
.929 
ADHD 14 58 34 1.92 .165 86 (40) 126 (60) .68 
controls 6 16 12 .03 .868 28 (41) 40 (59) .70 
DAT1 (3’UTR 
VNTR) 
  9/9 9/10 10/1
0 
 9R 10R 9/10  
 
.103 ADHD 3 40 63 1.29 .255 46 (22) 166 (78) .28 
controls 4 14 16 .12 .729 22 (32) 46 (68) .48 
DRD4 (Exon 3 
VNTR) 
  other 7/other 7/7  other 7 7/other  
.295 ADHD 69 34 5 .09 .758 172 (80) 44 (20) 3.91 
controls 26 8 1 .16 .693 60 () 10 6.00 
Hardy-Weinberg-Equilibrium (HWE) was tested with a Chi² procedure. For comparison of allele frequencies 
between groups, we used Fisher's exact test. SNAP25, synaptosomal-associated protein 25 kDa; SERT, serotonin 
transporter; TPH2, tryptophan hydroxylase 2; DAT1, dopamine transporter (SLC6A3); DRD4, dopamine 
receptor D4. 
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Supplementary Table S4: Association of each genotype with diagnostic status 
 Chi² P 
SNAP25 
+2015 (rs6077690) 
+80609 (rs363006) 
-523 (rs6039769) 
 
3.22 
3.65 
3.45 
 
0.200 
0.161 
0.178 
SERT (HTTLPR tri-allelic) 0.30 0.859 
TPH2 (rs4570625) 0.72 0.697 
DAT1 (3’UTR VNTR) 4.89 0.087 
DRD4 (Exon 3 VNTR) 1.30 0.523 
Annotation: SNAP25, synaptosomal-associated protein 25 kDa; SERT, serotonin transporter; TPH2, tryptophan 
hydroxylase 2; DAT1, dopamine transporter (SLC6A3); DRD4, dopamine receptor D4. 
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Supplementary Table S4: Correlations between age and gene expression  
 Correlation coefficient  p-value  
SLC6A3 - 0.087 0.323 
DRD4 - 0.042 0.623 
DRD5 - 0.035 0.687 
TPH1 - 0.174 0.039 
SERT   0.140 0.105 
SNAP25    0.136 0.115 
CRHBP - 0.071 0.412 
Annotation: SNAP25, synaptosomal-associated protein 25 kDa; SERT, serotonin transporter; TPH1, tryptophan 
hydroxylase 1; SLC6A3, dopamine transporter (DAT); DRD4, dopamine receptor D4; DRD5, dopamine receptor 
D5; CRHBP, corticotropin-releasing factor binding protein 
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Supplementary Table S5: Binary logistic regression model for SLC6A3, DRD5, TPH1 and 
SNAP25  
 P-value  OR (95% CI) Correct 
classification 
Total AUC 
TPH1 0.001 1.11 (1.04–1.18) 74.8 % 
0.917 
DRD5 0.010 1.28 (1.06–1.53) 82.4 % 
SNAP25 0.013 1.06 (1.01–1.12) 83.2 % 
SLC6A3 0.049 1.06 (1.00–1.11) 86.6 % 
Annotation: AUC, area under the curve; OR, odds ration; SNAP25, synaptosomal-associated protein 25 kDa; 
TPH1, tryptophan hydroxylase 1; SLC6A3, dopamine transporter (DAT); DRD5, dopamine receptor D5. 
 
Figure S1: Gene expression levels in peripheral blood samples of attention-deficit hyperactivity
disorder (ADHD) compared to controls. Statistical significance * p<0.05, ** p<0.001. Annotation: DAT,
dopamine transporter, DRD4, dopamine D4 receptor; DRD5, dopamine D6 receptor; CRHBP,
corticotropin-releasing factor binding protein; SNAP25, synaptosomal-associated protein of 25 kDa;
TPH1, tryptophan hydroxylase 1; SERT, serotonin transporter.
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Figure S2: Gene expression levels in peripheral blood samples of attention-deficit hyperactivity
disorder (ADHD) compared to controls- genotype influence of expression. The genotypes are: SNAP25
+2015 (rs6077690), +80609 (rs363006), -523 (rs6039769), TPH2 (rs4570625), DAT1 (3’UTR VNTR).
Statistical significance * p<0.05, ** p<0.001. Annotation: DAT, dopamine transporter, SNAP25,
synaptosomal-associated protein of 25 kDa; TPH1, tryptophan hydroxylase 1; TPH2, tryptophane
hydroxylase 2.
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